WO2008105507A1 - 脊髄損傷治療薬剤 - Google Patents

脊髄損傷治療薬剤 Download PDF

Info

Publication number
WO2008105507A1
WO2008105507A1 PCT/JP2008/053557 JP2008053557W WO2008105507A1 WO 2008105507 A1 WO2008105507 A1 WO 2008105507A1 JP 2008053557 W JP2008053557 W JP 2008053557W WO 2008105507 A1 WO2008105507 A1 WO 2008105507A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
spinal cord
cord injury
demyelinating disease
disclosed
Prior art date
Application number
PCT/JP2008/053557
Other languages
English (en)
French (fr)
Inventor
Hideyuki Okano
Yoshiaki Toyama
Masaya Nakamura
Akio Iwanami
Kazuya Kitamura
Toshikazu Nakamura
Hiroshi Funakoshi
Keigo Hanada
Original Assignee
Keio University
Osaka University
Kringle Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University, Osaka University, Kringle Pharma Inc. filed Critical Keio University
Priority to KR1020157033326A priority Critical patent/KR20150138413A/ko
Priority to JP2009501304A priority patent/JP5419045B2/ja
Priority to CA2675953A priority patent/CA2675953C/en
Priority to ES08721006T priority patent/ES2412388T3/es
Priority to DK08721006.8T priority patent/DK2116255T3/da
Priority to CN200880004651.0A priority patent/CN101610783B/zh
Priority to EP08721006.8A priority patent/EP2116255B1/en
Priority to KR1020097019957A priority patent/KR101670677B1/ko
Publication of WO2008105507A1 publication Critical patent/WO2008105507A1/ja
Priority to US12/548,881 priority patent/US8518880B2/en
Priority to HK10101945.2A priority patent/HK1134445A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本発明は、脊髄損傷及び脱髄性疾患を根本的に治療するのに有効な薬剤を提供することを目的とする。本発明の薬剤は、ＨＧＦ蛋白質を有効成分とする脊髄損傷治療剤及び脱髄性疾患治療剤である。
PCT/JP2008/053557 2007-02-28 2008-02-28 脊髄損傷治療薬剤 WO2008105507A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020157033326A KR20150138413A (ko) 2007-02-28 2008-02-28 척수 손상 치료제
JP2009501304A JP5419045B2 (ja) 2007-02-28 2008-02-28 脊髄損傷治療薬剤
CA2675953A CA2675953C (en) 2007-02-28 2008-02-28 Therapeutic agent for spinal cord injuries
ES08721006T ES2412388T3 (es) 2007-02-28 2008-02-28 Administración intratecal de FCH después de una lesión en la médula espinal
DK08721006.8T DK2116255T3 (da) 2007-02-28 2008-02-28 Intratekal indgivelse af hgf efter rygmarvsskade
CN200880004651.0A CN101610783B (zh) 2007-02-28 2008-02-28 脊髓损伤治疗剂
EP08721006.8A EP2116255B1 (en) 2007-02-28 2008-02-28 Intrathecal administration of hgf after spinal cord injury
KR1020097019957A KR101670677B1 (ko) 2007-02-28 2008-02-28 척수 손상 치료제
US12/548,881 US8518880B2 (en) 2007-02-28 2009-08-27 Therapeutic agent for spinal cord injuries
HK10101945.2A HK1134445A1 (en) 2007-02-28 2010-02-24 Intrathecal administration of hgf after spinal cord injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2007/053804 WO2008105088A1 (ja) 2007-02-28 2007-02-28 脊髄損傷治療薬剤
JPPCT/JP2007/053804 2007-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/053804 Continuation-In-Part WO2008105088A1 (ja) 2007-02-28 2007-02-28 脊髄損傷治療薬剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/548,881 Continuation US8518880B2 (en) 2007-02-28 2009-08-27 Therapeutic agent for spinal cord injuries

Publications (1)

Publication Number Publication Date
WO2008105507A1 true WO2008105507A1 (ja) 2008-09-04

Family

ID=39720932

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2007/053804 WO2008105088A1 (ja) 2007-02-28 2007-02-28 脊髄損傷治療薬剤
PCT/JP2008/053557 WO2008105507A1 (ja) 2007-02-28 2008-02-28 脊髄損傷治療薬剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/053804 WO2008105088A1 (ja) 2007-02-28 2007-02-28 脊髄損傷治療薬剤

Country Status (10)

Country Link
US (1) US8518880B2 (ja)
EP (1) EP2116255B1 (ja)
KR (2) KR20150138413A (ja)
CN (2) CN101610783B (ja)
CA (1) CA2675953C (ja)
DK (1) DK2116255T3 (ja)
ES (1) ES2412388T3 (ja)
HK (1) HK1134445A1 (ja)
PT (1) PT2116255E (ja)
WO (2) WO2008105088A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010041716A1 (ja) * 2008-10-10 2010-04-15 クリングルファーマ株式会社 腱骨移行部組織または靭帯骨移行部組織の再生促進剤
JP2014517695A (ja) * 2011-05-23 2014-07-24 アジュ ユニヴァーシティー インダストリー−アカデミック コーオペレイション ファウンデーション 肝細胞増殖因子の遺伝子と、塩基性ヘリックスループヘリックスモチーフを有する神経原性転写因子の遺伝子とを導入した成体幹細胞株、及びその使用
US10213485B2 (en) 2014-09-10 2019-02-26 Kringle Pharma Inc. HGF preparation suitable for treatment of neurological disorders
JP2022522941A (ja) * 2019-01-07 2022-04-21 ベイジン・ノースランド・バイオテック・カンパニー・リミテッド ヒト肝細胞増殖因子変異体およびその使用
WO2023171808A1 (ja) * 2022-03-11 2023-09-14 慶應義塾 脊髄損傷治療剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018069A1 (ja) * 2010-08-06 2012-02-09 大日本住友製薬株式会社 脊髄損傷治療用製剤
US10716564B2 (en) 2017-02-17 2020-07-21 Ethicon Llc Stapling adjunct attachment
US10478280B2 (en) * 2017-02-17 2019-11-19 Ethicon Llc Methods and devices for delivering and securing adjunct materials to a treatment site
CN113433324B (zh) * 2021-05-28 2022-11-18 南通大学 Nck1蛋白作为标志物在诊断脊髓损伤中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6128521A (ja) 1984-07-06 1986-02-08 Wako Pure Chem Ind Ltd 新規重合体及びその製造法
JPH05111382A (ja) 1991-10-22 1993-05-07 Saito Signal Kenkyusho:Kk ヒト好酸球細胞株
WO2003045439A1 (fr) 2001-11-28 2003-06-05 Anges Mg, Inc. Preparations medicinales contenant du materiel genetique destinees au traitement de maladies neurodegeneratives
WO2005100577A1 (en) 2004-04-14 2005-10-27 Agency For Science, Technology And Research Method for gene delivery to neuronal cells
WO2006077675A1 (ja) * 2005-01-24 2006-07-27 Kringle Pharma Inc. 移植臓器の線維化抑制剤
WO2007032396A1 (ja) * 2005-09-16 2007-03-22 Keio University 脊髄損傷治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143714A (en) * 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US7033608B1 (en) * 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
WO2004021992A2 (en) * 2002-09-06 2004-03-18 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
CN1250287C (zh) * 2002-11-20 2006-04-12 中国人民解放军军事医学科学院放射医学研究所 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用
JP2005035945A (ja) * 2003-07-16 2005-02-10 Cardio Corp 組織再生複合療法
JP2007238487A (ja) 2006-03-07 2007-09-20 Osaka Univ 脊髄損傷に対する嗅粘膜移植にｈｇｆを用いた神経機能再建法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6128521A (ja) 1984-07-06 1986-02-08 Wako Pure Chem Ind Ltd 新規重合体及びその製造法
JPH05111382A (ja) 1991-10-22 1993-05-07 Saito Signal Kenkyusho:Kk ヒト好酸球細胞株
WO2003045439A1 (fr) 2001-11-28 2003-06-05 Anges Mg, Inc. Preparations medicinales contenant du materiel genetique destinees au traitement de maladies neurodegeneratives
WO2005100577A1 (en) 2004-04-14 2005-10-27 Agency For Science, Technology And Research Method for gene delivery to neuronal cells
WO2006077675A1 (ja) * 2005-01-24 2006-07-27 Kringle Pharma Inc. 移植臓器の線維化抑制剤
WO2007032396A1 (ja) * 2005-09-16 2007-03-22 Keio University 脊髄損傷治療剤

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 122, 1984, pages 1450 - 1459
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 163, 1989, pages 967
CLIN. CHIM ACTA., vol. 327, 2003, pages 1 - 23
IWANAMI A.: "Sekizui Sonsho ni Taisuru Hepatocyte Growth Factor (HGF) no Yukosei no Kento", THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, vol. 79, no. 8, 2005, pages S764, XP003010152 *
KITAMURA H.: "Sekizui Sonsho ni Taisuru Hepatocyte Growth Factor no Yukosei no Kento", THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, vol. 80, no. 8, 2006, pages S884, XP003023237 *
KITAMURA K.: "Sekizui Sonsho ni Taisuru Hepatocyte Growth Factor no Yokusei no Kento", JOURNAL OF THE JAPAN SPINE RESEARCH SOCIETY, vol. 17, no. 1, 2006, pages 557, XP003023238 *
M. BODANSZKY; M.A. ONDETTI: "Peptide Synthesis", 1966, INTERSCIENCE PUBLISHERS
NAT. NEUROSCI., vol. 2, 1999, pages 213 - 217
NATURE, vol. 342, 1989, pages 440 - 443
SCHROEDER; LUEBKE: "The Peptide", 1965, ACADEMIC PRESS
See also references of EP2116255A4
THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, vol. 79, no. 8, 25 August 2005 (2005-08-25), pages S764

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010041716A1 (ja) * 2008-10-10 2010-04-15 クリングルファーマ株式会社 腱骨移行部組織または靭帯骨移行部組織の再生促進剤
EP2351574A4 (en) * 2008-10-10 2012-03-28 Kringle Pharma Inc PROMOTER TO REGENERATE TEN-BONE JOINTS OR BAND BONE JOINTS
US8927493B2 (en) 2008-10-10 2015-01-06 Kringle Pharma, Inc. Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
JP2014517695A (ja) * 2011-05-23 2014-07-24 アジュ ユニヴァーシティー インダストリー−アカデミック コーオペレイション ファウンデーション 肝細胞増殖因子の遺伝子と、塩基性ヘリックスループヘリックスモチーフを有する神経原性転写因子の遺伝子とを導入した成体幹細胞株、及びその使用
US10213485B2 (en) 2014-09-10 2019-02-26 Kringle Pharma Inc. HGF preparation suitable for treatment of neurological disorders
US10702582B2 (en) 2014-09-10 2020-07-07 Kringle Pharma Inc. HGF preparation suitable for treatment of neurological disorders
JP2022522941A (ja) * 2019-01-07 2022-04-21 ベイジン・ノースランド・バイオテック・カンパニー・リミテッド ヒト肝細胞増殖因子変異体およびその使用
JP7246494B2 (ja) 2019-01-07 2023-03-27 ベイジン・ノースランド・バイオテック・カンパニー・リミテッド ヒト肝細胞増殖因子変異体およびその使用
WO2023171808A1 (ja) * 2022-03-11 2023-09-14 慶應義塾 脊髄損傷治療剤

Also Published As

Publication number Publication date
CN105311620A (zh) 2016-02-10
US20100081617A1 (en) 2010-04-01
CN101610783B (zh) 2016-11-16
CN101610783A (zh) 2009-12-23
CA2675953C (en) 2016-05-10
KR20150138413A (ko) 2015-12-09
CA2675953A1 (en) 2008-09-04
HK1134445A1 (en) 2010-04-30
ES2412388T3 (es) 2013-07-11
WO2008105088A1 (ja) 2008-09-04
KR101670677B1 (ko) 2016-11-01
EP2116255B1 (en) 2013-04-10
PT2116255E (pt) 2013-06-21
US20120021040A9 (en) 2012-01-26
EP2116255A1 (en) 2009-11-11
EP2116255A4 (en) 2011-05-04
US8518880B2 (en) 2013-08-27
DK2116255T3 (da) 2013-05-13
KR20090118078A (ko) 2009-11-17

Similar Documents

Publication Publication Date Title
WO2008105507A1 (ja) 脊髄損傷治療薬剤
WO2008096775A1 (ja) 疼痛疾患治療剤
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP1937633B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2008128740A8 (en) Titration of tapentadol
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
BRPI0617077A2 (pt) Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2006100677A3 (en) Device and method for pupil size modulation
WO2008137780A3 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2007135026A3 (de) Substituierte pteridine als therapeutika
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007025229A3 (en) Compositions and their uses directed to hsp27
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880004651.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721006

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008721006

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2675953

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009501304

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097019957

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020157033323

Country of ref document: KR

Ref document number: 1020157033326

Country of ref document: KR